HIPEC with cisplatin desensitization at the time of secondary debulking in a patient with a prior carboplatin hypersensitivity reaction

This case, to our knowledge, is the first reported in gynecologic oncology to demonstrate the feasibility of safely delivering HIPEC with cisplatin in a patient with prior carboplatin hypersensitivity. As HIPEC adoption expands in platinum-sensitive recurrent ovarian cancer, platinum hypersensitivity will become an increasing challenge. This report underscores the need for further study of intraperitoneal desensitization strategies and cross-reactivity risks, offering a potential for extending HIPEC to patients with platinum hypersensitivity.